This is a working overview of LC-MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The macroamylase molecules are unable to pass through the kidneys and are therefore retained in the blood, leading to elevated levels of amylase in the bloodstream. In contrast, amylase urine levels are normal.
Fig. 2 shows a typical PTR-MS measurement performed in food and flavor research. The test person swallows a sip of a vanillin flavored drink and breathes via his nose into a heated inlet device coupled to a PTR-MS instrument. Due to the high time resolution and sensitivity of the instrument used here, the development of vanillin in the person's breath can be monitored in real-time (please note that isoprene is shown in this figure because it is a product of human metabolism and therefore acts as an indicator for the breath cycles). The data can be used for food design, i.e. for adjusting the intensity and duration of vanillin flavor tasted by the consumer.
Insulated shipping containers are a type of packaging used to ship temperature sensitive products such as foods, pharmaceuticals, organs, blood, biologic materials, vaccines and chemicals. They are used as part of a cold chain to help maintain product freshness and efficacy. The term can also refer to insulated intermodal containers or insulated swap bodies.
Sources: en.wikipedia.org
=== Catabolic pathway (catabolism) === A catabolic pathway is a series of reactions that bring about a net release of energy in the form of a high energy phosphate bond formed with the energy carriers adenosine diphosphate (ADP) and guanosine diphosphate (GDP) to produce adenosine triphosphate (ATP) and guanosine triphosphate (GTP), respectively. The net reaction is, therefore, thermodynamically favorable, for it results in a lower free energy for the final products. A catabolic pathway is an exergonic system that produces chemical energy in the form of ATP, GTP, NADH, NADPH, FADH2, etc. from energy containing sources such as carbohydrates, fats, and proteins. The end products are often carbon dioxide, water, and ammonia. Coupled with an endergonic reaction of anabolism, the cell can synthesize new macromolecules using the original precursors of the anabolic pathway. An example of a coupled reaction is the phosphorylation of fructose-6-phosphate to form the intermediate fructose-1,6-bisphosphate by the enzyme phosphofructokinase accompanied by the hydrolysis of ATP in the pathway of glycolysis. The resulting chemical reaction within the metabolic pathway is highly thermodynamically favorable and, as a result, irreversible in the cell.
=== Pharmacodynamics === SR-17018 acts as a biased partial agonist of the μ-opioid receptor (MOR), with strong selectivity for activation of G protein signaling over β-arrestin2 recruitment. Its affinities (Ki) for the human opioid receptors have been reported to be 11 nM for the MOR, 68 nM for the κ-opioid receptor (KOR), and >10,000 nM for the δ-opioid receptor (DOR). In terms of MOR activation, the drug had activational potencies and efficacies (EC50Tooltip half-maximal effective concentration and EmaxTooltip maximal efficacy) of 97–193 nM (72–75%) for GTPγS binding, 76 nM (105%) for cAMPTooltip cyclic adenosine monophosphate accumulation, and >10,000 nM (10%) for β-arrestin2 recruitment. Both GTPγS binding and cAMP accumulation are measures of G protein signaling. The drug showed a calculated bias factor for GTPγS binding over β-arrestin2 recruitment of 80 to 100 relative to DAMGO. SR-17018 also showed strong bias for G protein activation over β-arrestin2 recruitment using mouse proteins, albeit with reduced efficacy for GTPγS binding (Emax = 37%). β-Arrestin2 activation may contribute to opioid tolerance, though it is not the only mechanism of tolerance to these drugs. SR-17018 shows a strikingly different MOR phosphorylation profile from other MOR biased, partial, and full agonists. Additional studies have characterized the interactions of SR-17018 with the MOR, including activational potencies and efficacies at downstream signaling pathways, as well.
== History == The efficacy of azacitidine to treat juvenile myelomonocytic leukemia was evaluated in AZA-JMML-001 (NCT02447666), an international, multicenter, open-label study to evaluate the pharmacokinetics, pharmacodynamics, safety, and activity of azacitidine prior to hematopoietic stem cell transplantation in 18 pediatric patients with juvenile myelomonocytic leukemia.
Sources: en.wikipedia.org
Vasculitis a disorder where blood vessels are destroyed by inflammation. Can be life-threatening if it affects the right blood vessels. Galactorrhoea (lactation that is not associated with pregnancy or breast feeding) Delayed micturition (that is, delays in urination from when a conscious effort to urinate is made) Hyperthermia (elevation of body temperature; its seriousness depends on the extent of the hyperthermia) Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) this is basically when the body's level of the hormone, antidiuretic hormone, which regulates the conservation of water and the restriction of blood vessels, is elevated. This is potentially fatal as it can cause electrolyte abnormalities including hyponatraemia (low blood sodium), hypokalaemia (low blood potassium) and hypocalcaemia (low blood calcium) which can be life-threatening. Agranulocytosis a drop in white blood cell counts. The white blood cells are the cells of the immune system that fight off foreign invaders. Hence agranulocytosis leaves an individual open to life-threatening infections. Leukopaenia the same as agranulocytosis but less severe. Neuroleptic malignant syndrome (a potentially fatal reaction to antidopaminergic agents, most often antipsychotics. It is characterised by hyperthermia, diarrhoea, tachycardia, mental status changes [e.g. confusion], rigidity, extrapyramidal side effects) Tardive dyskinesia a most often irreversible neurologic reaction to antidopaminergic treatment, characterised by involuntary movements of facial muscles, tongue, lips, and other muscles.
Alniditan acts as a selective serotonin 5-HT1B and 5-HT1D receptor full agonist. To a much lesser extent, it is also a full agonist of the serotonin 5-HT1A receptor and an agonist of the serotonin 5-HT2B receptor. Conversely, alniditan is essentially inactive at the serotonin 5-HT1E, 5-HT1F, and 5-HT2A receptors. The broad receptor interactions of alniditan have been studied and reported.
Both these levels are raised to be close in energy to the 7s ones, high enough to possibly be chemically active. This would allow for the possibility of exotic nihonium compounds without lighter group 13 analogues. Periodic trends would predict nihonium to have an atomic radius larger than that of thallium due to it being one period further down the periodic table, but calculations suggest nihonium has an atomic radius of about 170 pm, the same as that of thallium, due to the relativistic stabilisation and contraction of its 7s and 7p1/2 orbitals. Thus, nihonium is expected to be much denser than thallium, with a predicted density of about 16 to 18 g/cm3 compared to thallium's 11.85 g/cm3, since nihonium atoms are heavier than thallium atoms but have the same volume. Bulk nihonium is expected to have a hexagonal close-packed crystal structure, like thallium. The melting and boiling points of nihonium have been predicted to be 430 °C and 1100 °C respectively, exceeding the values for indium and thallium, following periodic trends. Nihonium should have a bulk modulus of 20.8 GPa, about half that of thallium (43 GPa).
== Thoracic and Respiratory == Adenocarcinoma of the lung Basaloid squamous cell lung carcinoma Bronchial adenomas/carcinoids Giant-cell carcinoma of the lung Large-cell lung carcinoma Large cell lung carcinoma with rhabdoid phenotype Laryngeal cancer Mesothelioma Non-small cell lung cancer Non-small cell lung carcinoma Pleuropulmonary blastoma Sarcomatoid carcinoma of the lung Small cell lung cancer Squamous-cell carcinoma of the lung Thymoma and thymic carcinoma
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.